![Separator Separator](https://www.siliconindia.com/images/simag_images//images/line.png)
India Ranks Fourth Globally For Healthtech VC Investment Since 2016
![Separator Separator](https://www.siliconindia.com/images/simag_images//images/line.png)
The global coronavirus pandemic has accelerated the demand for new innovations in health technology, with latest data from London & Partners and Dealroom.co showing a record $51.3 billion has been pumped into global healthtech startups already this year, up 280 percent on 2016 levels.
So far in 2021, Indian healthtech startups have attracted $1.9 billion in VC investment, coming in fourth globally. The US leads with $31.9 billion in VC investment, while the UK comes in third with $3.8 billion, close behind China's $4.1 billion. India also ranked among the top five countries for investment into healthtech since 2016 with a total of $4.4bn, increasing ten times between 2016 and 2021.
Indian and the UK are amongst the fastest growing regions for healthtech investment, with UK healthtech VC investment rising from just $420 million in 2016 to $3.8 billion, an increase by nine times and Indian healthtech investment rising from $190 million to $1.9 billion, growing 10 times.
London and Mumbai also both feature in the top 15 list of global hubs for healthtech VC investment, demonstrating increasing opportunities for collaboration between the two regions. In Europe, London is the leading hub for healthtech investment over the last five years, with investment growing 11.1 times, faster than in the Bay Area, New York and Boston. So far this year, London-based healthtech firms have received $1 billion in VC investment. In Mumbai, healthtech VC investment has increased from $100 million in 2016 to $1.2 billion in 2021, clocking a record 121x growth for the period.
There has been an increase in the number of major funding rounds for Indian health-tech companies in 2021, including three rounds for PharmEasy ($350m Series E in April, $500 million Series F in July and $204 million Series G in October) and $164 million growth equity for Star Health.
Hemin Bharucha, Country Director, India, London & Partners said, "Healthtech innovation has been growing rapidly in recent years and it is fantastic to see both India and the UK attracting record levels of investment into the sector. Cities like Mumbai and London are two of the fastest growing hubs globally for healthtech investment, suggesting there are lots of opportunities for future collaboration between the two regions. We look forward to supporting Indian healthtech companies to access London's thriving healthtech ecosystem".
So far in 2021, Indian healthtech startups have attracted $1.9 billion in VC investment, coming in fourth globally. The US leads with $31.9 billion in VC investment, while the UK comes in third with $3.8 billion, close behind China's $4.1 billion. India also ranked among the top five countries for investment into healthtech since 2016 with a total of $4.4bn, increasing ten times between 2016 and 2021.
Indian and the UK are amongst the fastest growing regions for healthtech investment, with UK healthtech VC investment rising from just $420 million in 2016 to $3.8 billion, an increase by nine times and Indian healthtech investment rising from $190 million to $1.9 billion, growing 10 times.
London and Mumbai also both feature in the top 15 list of global hubs for healthtech VC investment, demonstrating increasing opportunities for collaboration between the two regions. In Europe, London is the leading hub for healthtech investment over the last five years, with investment growing 11.1 times, faster than in the Bay Area, New York and Boston. So far this year, London-based healthtech firms have received $1 billion in VC investment. In Mumbai, healthtech VC investment has increased from $100 million in 2016 to $1.2 billion in 2021, clocking a record 121x growth for the period.
There has been an increase in the number of major funding rounds for Indian health-tech companies in 2021
There has been an increase in the number of major funding rounds for Indian health-tech companies in 2021, including three rounds for PharmEasy ($350m Series E in April, $500 million Series F in July and $204 million Series G in October) and $164 million growth equity for Star Health.
Hemin Bharucha, Country Director, India, London & Partners said, "Healthtech innovation has been growing rapidly in recent years and it is fantastic to see both India and the UK attracting record levels of investment into the sector. Cities like Mumbai and London are two of the fastest growing hubs globally for healthtech investment, suggesting there are lots of opportunities for future collaboration between the two regions. We look forward to supporting Indian healthtech companies to access London's thriving healthtech ecosystem".